Merck's Molnupiravir vs. Ivermectin

One paper compared Merck's data on molnupiravir against peer-reviewed data on ivermectin and found ivermectin has a low side effect profile, costs less than molnupiravir and is more effective against SARS-CoV-2
   
Clinical Trials data show Merck gathered 1,850 participants but released data on only 762 in the non-hospitalized arm of the study. The study with hospitalized patients anticipated 1,300 participants, but enrolled 304 before terminating for "business reasons"

Merck has applied for emergency use authorization for molnupiravir against COVID-19. Some are excited about an antiviral that may be effective against the virus, but the exclusion criteria for participants in the study may mean few will qualify to take the drug
   
For many, prophylaxis and early treatment do not require prescription medication. Optimize your vitamin D level to help prevent the illness, and use nebulized hydrogen peroxide after exposure or in combination with nutraceuticals for early treatment 

Read the full analysis by Dr. Mercola

 

 

George W. Bush: The terrorists want to change our lifestyle